针对埃博拉病毒的疫苗
综述回顾埃博拉疫苗研发历史,指出2014年疫情加速了多种候选疫苗的临床开发,rVSV载体疫苗在疫情现场采用环形疫苗接种策略显示出高效力,但未来仍需获得可部署的许可疫苗以应对扎伊尔和苏丹型埃博拉病毒。
要点
- 2014年埃博拉疫情前全球疫苗研发动力有限,疫情推动多种候选疫苗加速临床开发。
- rVSV载体疫苗在疫情现场采用环形疫苗接种策略显示出高效力。
- 未来需确保获得可部署的许可疫苗以应对至少扎伊尔和苏丹型埃博拉病毒。
核心结论
- 尽管世卫组织已解除国际关注的突发公共卫生事件,全球科学界仍面临确保获得可部署的许可疫苗以应对未来至少扎伊尔和苏丹型埃博拉病毒疫情的诸多挑战。
- 保护持久性、免疫学机制相关性和优选部署策略仍存在若干未解问题。
研究设计与样本
- 综述简要梳理埃博拉疫苗研发历史、疫情规模显现后取得的重大进展、部分经验教训及其对未来疫苗开发和类似疫情管理的启示。
主要发现
- 2014年之前,自1976年发现该病毒以来,全球研发疫苗的动力有限。
- 2014年疫情导致大量生命损失,但通过世卫组织协调的全球协作,显著加速了多种候选疫苗的临床开发。
- 已获得多种疫苗在高加索人和非洲人群中大量的安全性和免疫原性数据。
- 测试rVSV载体疫苗的里程碑式效力试验显示,在疫情现场采用环形疫苗接种策略部署时具有高效力。
局限性
- 保护持久性、免疫学机制相关性和优选部署策略仍存在若干未解问题。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We have just witnessed the largest and most devastating outbreak of Ebola virus disease, which highlighted the urgent need for development of an efficacious vaccine that could be used to curtail future outbreaks. Prior to 2014, there had been limited impetus worldwide to develop a vaccine since the virus was first discovered in 1976. Though too many lives were lost during this outbreak, it resulted in the significantly accelerated clinical development of a number of candidate vaccines through an extraordinary collaborative global effort coordinated by the World Health Organisation (WHO) and involving a number of companies, trial centres, funders, global stakeholders and agencies. We have acquired substantial safety and immunogenicity data on a number of vaccines in Caucasian and African populations. The rapid pace of events led to the initiation of the landmark efficacy trial testing the rVSV-vectored vaccine, which showed high level efficacy in an outbreak setting when deployed using an innovative ring vaccination strategy. Though the Public Health Emergency of International Concern (PHEIC) declared by the WHO has now been lifted, the global scientific community faces numerous challenges ahead to ensure that there is a licensed, deployable vaccine available for use in future outbreaks for at least the Zaire and Sudan strains of Ebola virus. There remain several unanswered questions on the durability of protection, mechanistic immunological correlates and preferred deployment strategies. This review outlines a brief history of the development of Ebola vaccines, the significant progress made since the scale of the outbreak became apparent, some lessons learnt and how they could shape future development of vaccines and the management of similar outbreaks.
引用
- Venkatraman N, Silman D, Folegatti PM, et al. Vaccines against Ebola virus. Vaccine. 2017. PMID: 28780120. doi:10.1016/j.vaccine.2017.07.054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。